Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carl Zeiss Meditec AGXSWX:AFX -2.60%78 3-Year Revenue Growth Rate is 6.20% as of Mar. 2026, which is 9% below its 10-year median of 6.80. GuruFocus rates XSWX:AFX with a GF Score™ of 78/100 and a GF Value™ of CHF71.65. The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 57.84% on this metric.
During the past 12 months, Carl Zeiss Meditec AG's average Revenue per Share Growth Rate was 8.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Carl Zeiss Meditec AG was 16.10% per year. The lowest was -13.10% per year. And the median was 6.80% per year.
Carl Zeiss Meditec AG (XSWX:AFX) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Carl Zeiss Meditec AG 3-Year Revenue Growth Rate Related Terms
XSWX:AFX vs ISRG, BDX, RMD: 3-Year Revenue Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG 3-Year Revenue Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's 3-Year Revenue Growth Rate falls into.
Carl Zeiss Meditec AG 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 6.20% mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a 3-Year Revenue Growth Rate of 6.20% as of Mar. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Carl Zeiss Meditec AG and its competitors. This is near median its historical median of 6.80. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #320 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 42.2%.
Is Carl Zeiss Meditec AG's 3-Year Revenue Growth Rate too high?
Carl Zeiss Meditec AG's current 3-Year Revenue Growth Rate of 6.20% is near median its 10-year median of 6.80. The Medical Devices & Instruments industry median 3-Year Revenue Growth Rate is 3.80. Carl Zeiss Meditec AG's value of 6.20% is 63.2% above this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #320 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's 3-Year Revenue Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #320 out of 759 companies for 3-Year Revenue Growth Rate. This puts Carl Zeiss Meditec AG in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 3.80. Carl Zeiss Meditec AG's value of 6.20% is 63.2% above this benchmark. While the company's 10-year median is 6.80 vs. the industry median of 3.80, Carl Zeiss Meditec AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Revenue Growth Rate among Medical Devices & Instruments companies is 3.80, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current 3-Year Revenue Growth Rate of 6.20% is 63.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Revenue Growth Rate is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current 3-Year Revenue Growth Rate is 6.20%, which is near median its own 10-year median of 6.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Carl Zeiss Meditec AG (XSWX:AFX) has a current 3-Year Revenue Growth Rate of 6.20%. The stock's GF Value™ is CHF71.65, compared to a current price of CHF28.46 — trading 60.3% below its estimated fair value. The current 3-Year Revenue Growth Rate is 6.20%, which is near median its 10-year median of 6.80 and 63.2% above the Medical Devices & Instruments industry median of 3.80. Carl Zeiss Meditec AG's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current 3-Year Revenue Growth Rate is 6.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF28.46 is trading 60.3% below its estimated GF Value™ of CHF71.65.
Key valuation signals for XSWX:AFX:
3-Year Revenue Growth Rate: 6.20% (near median its 10-year median of 6.80)
GF Value™: CHF71.65 vs. price of CHF28.46 (60.3% below fair value)
Industry Position: 63.2% above the Medical Devices & Instruments median (#320 of 759)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
78GF Score
Get the complete analysis for XSWX:AFX
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
